JPH072640A - External preparation for protecting ultraviolet disorder - Google Patents
External preparation for protecting ultraviolet disorderInfo
- Publication number
- JPH072640A JPH072640A JP29159892A JP29159892A JPH072640A JP H072640 A JPH072640 A JP H072640A JP 29159892 A JP29159892 A JP 29159892A JP 29159892 A JP29159892 A JP 29159892A JP H072640 A JPH072640 A JP H072640A
- Authority
- JP
- Japan
- Prior art keywords
- external preparation
- hydroxybenzaldehyde
- ultraviolet
- skin
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、紫外線暴露によって引
き起こされる種々の生体障害を防御する外用剤に関する
ものであって、化粧料基剤や軟膏に配合され、美白,日
焼け,肌荒れ防止等に有用である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for protecting various biological disorders caused by exposure to ultraviolet rays, which is compounded in a cosmetic base or an ointment and is useful for whitening, sunburning, preventing rough skin, etc. Is.
【0002】[0002]
【従来の技術】近年、紫外線暴露によって人の皮膚が受
ける様々な障害が問題となりつつある。通常、人間が被
る紫外線はその大部分が太陽光線である。そしてこの太
陽光線に含まれ地上に到達する紫外線は、290〜32
0nmの中波長紫外線(以下UVBという)と320〜
400nmの長波長紫外線(以下UVAという)とに大
別できる。UVBについては人の皮膚に対して急性の炎
症(紅斑)と火傷(sun−burn)を引き起こし、
しみ、そばかすの発生原因もしくは悪化原因、更には皮
膚癌の原因の主要な因子とも考えられており、その防御
策が早くから検討されている。UVAについては人の皮
膚への影響は一次黒化(Suntanning)程度と
考えられていたが、地表におけるUVAの照射量がUV
Bのそれの約15倍にも達し、それが真皮内に到達する
ことが近年確認された結果、UVAが血管壁や結合組織
中の弾性繊維に微慢性の変化をもたらし、皮膚を老化へ
と導くとともに、UVB照射効果の増強を引き起こすこ
とが予想されるに至り、UVAの防御手段にも大きな関
心がもたれるようになってきた。2. Description of the Related Art In recent years, various obstacles to human skin due to exposure to ultraviolet rays have become a problem. Usually, most of the ultraviolet rays that humans receive are sun rays. And the ultraviolet rays contained in this sunlight and reaching the ground are 290 to 32
320nm with 0nm medium wavelength ultraviolet ray (hereinafter referred to as UVB)
It can be roughly classified into 400 nm long-wavelength ultraviolet light (hereinafter referred to as UVA). UVB causes acute inflammation (erythema) and sun-burn on human skin,
It is also considered to be a major factor responsible for the generation or exacerbation of spots and freckles, as well as the cause of skin cancer, and its protective measures have been investigated from an early stage. Regarding UVA, the effect on human skin was thought to be about primary blackening (Suntaning), but the UVA irradiation dose on the ground surface was UV.
As a result of the recent confirmation that it reaches about 15 times that of B and reaches the inside of the dermis, UVA causes microchronic changes in elastic fibers in the blood vessel wall and connective tissue, leading to aging of the skin. With the introduction, it has been expected that it will cause an increase in the UVB irradiation effect, and there has been great interest in UVA protection measures.
【0003】従来の紫外線防御手段としては、紫外線吸
収剤(サンスクリーン剤)の使用が最も一般的である。
しかしながら、これらの紫外線吸収剤は紫外線が皮膚に
到達することを防ぐ目的で用いられているが、実際には
完全な紫外線遮蔽は困難である。このために、皮膚自体
の紫外線障害を防止する方法が模索されている。As the conventional means for protecting ultraviolet rays, the use of ultraviolet absorbers (sunscreen agents) is the most common.
However, although these UV absorbers are used for the purpose of preventing UV rays from reaching the skin, it is actually difficult to completely block UV rays. For this reason, methods for preventing the UV damage of the skin itself are being sought.
【0004】最近の研究結果より上述のような紫外線に
よる皮膚障害は、紫外線による皮膚脂質の酸化が大きな
原因となっていると考えられるようになってきた。そこ
で、紫外線による皮膚障害緩和に抗酸化剤を利用すると
いう考え方が提案された。もちろん、従来より各種抗酸
化剤が化粧料等に配合されているが、これらは通常その
化粧料自体に含まれる油脂成分の酸化防止を目的とした
ものである。しかも、ブチルヒドロキシアニソール(B
HA)、ブチルヒドロキシトルエン(BHT)等の合成
抗酸化剤は、一般的な抗酸化能は優れているものの安全
性の点から使用目的、使用量が厳しく制限されている。
一方、安全性の点では問題の少ないα−トコフェロール
等の天然抗酸化剤は、食品などの油脂類への抗酸化能は
期待できるものの、紫外線障害防御能は極めて低いとい
われている。したがって、安全性の面で問題の少ない天
然物由来の紫外線障害防御剤の開発が望まれる。From the recent research results, it has come to be considered that the above-mentioned skin damage due to ultraviolet rays is largely caused by the oxidation of skin lipids due to ultraviolet rays. Therefore, the idea of using an antioxidant to alleviate skin damage caused by ultraviolet rays was proposed. Of course, various antioxidants have been conventionally blended in cosmetics and the like, but these are usually for the purpose of preventing the oxidation of oil and fat components contained in the cosmetic itself. Moreover, butylhydroxyanisole (B
Although synthetic antioxidants such as HA) and butylhydroxytoluene (BHT) have excellent general antioxidant ability, their purpose and amount are strictly limited from the viewpoint of safety.
On the other hand, natural antioxidants such as α-tocopherol, which is less problematic in terms of safety, can be expected to have antioxidant ability against oils and fats such as foods, but are said to have extremely low UV damage-protecting ability. Therefore, it is desired to develop a UV-protective agent derived from a natural product, which is less problematic in terms of safety.
【0005】[0005]
【発明が解決しようとする課題】本発明は以上のような
状況に鑑みてなされたものであって、その目的は安定
性、安全性に優れ、外用剤として用いることができ、優
れた紫外線障害防御効果を有する薬剤を提供することに
ある。SUMMARY OF THE INVENTION The present invention has been made in view of the above circumstances, and its object is excellent stability and safety, can be used as an external preparation, and is excellent in UV damage. It is to provide a drug having a protective effect.
【0006】[0006]
【課題を解決するための手段】上記課題を解決すること
のできた本発明の紫外線障害防御外用剤は、p−ヒドロ
キシベンズアルデヒドを有効成分として含有することに
要旨を有する。The external agent for protecting against UV damage of the present invention, which has been able to solve the above problems, is characterized in that it contains p-hydroxybenzaldehyde as an active ingredient.
【0007】[0007]
【作用】本発明者らは、紫外線障害防御外用剤について
種々検討した結果、p−ヒドロキシベンズアルデヒドが
紫外線照射によって起こる種々の皮膚障害の一義的原因
といわれる皮膚脂質の過酸化を抑制することを見出し
た。更にこの化合物は紫外線障害防御効果に優れ、外用
剤として化粧料基剤や軟膏基剤等に配合した場合、安定
性等に優れていることを見出し、本発明の完成に至った
ものである。The present inventors have conducted various studies on external preparations for protection against UV damage and found that p-hydroxybenzaldehyde suppresses peroxidation of skin lipids, which is said to be the primary cause of various skin damage caused by UV irradiation. It was Further, they have found that this compound has an excellent effect of protecting against ultraviolet rays and is excellent in stability and the like when compounded as an external preparation in a cosmetic base, an ointment base or the like, and thus completed the present invention.
【0008】p−ヒドロキシベンズアルデヒドは種々の
植物に少量存在する化合物であり、制癌作用(特開昭5
5−51018号公報)等が知られている。その急性毒
性LD50は4000mg/kg体重(ラット、経口)で
ある。p−ヒドロキシベンズアルデヒドの製造方法は特
に限定されず、例えばまた化学合成法としてはReim
er Tiemano法、電解還元法等を採用すること
ができる。[0008] p-Hydroxybenzaldehyde is a compound which is present in small amounts in various plants, and has an anti-cancer effect (Japanese Patent Laid-Open No. 5-58200).
5-51018) and the like are known. Its acute toxicity LD 50 is 4000 mg / kg body weight (rat, oral). The method for producing p-hydroxybenzaldehyde is not particularly limited. For example, as a chemical synthesis method, Reim
er Tiemano method, electrolytic reduction method and the like can be adopted.
【0009】本発明の外用剤は、紫外線障害の防止を目
的とする用途であればクリーム,化粧水,パック,パウ
ダー,ファウンデーション等の化粧料の他に、乳剤,ロ
ーション剤,軟膏剤等の医薬部外品など種々の外用形態
に製剤でき、それぞれの製剤において常用されている基
剤,賦形剤,安定剤,顔料,香料,防腐剤,金属封鎖
剤,有機酸などを適宜配合してもよい。また紫外線障害
防御効果を更に高めるために、紫外線遮断剤或は紫外線
吸収剤を配合することも勿論有効である。The external preparation of the present invention is used for the purpose of preventing UV damage, in addition to cosmetics such as creams, lotions, packs, powders and foundations, pharmaceuticals such as emulsions, lotions and ointments. It can be formulated into various external forms such as quasi-drugs, and the bases, excipients, stabilizers, pigments, fragrances, preservatives, sequestering agents, organic acids, etc., which are commonly used in each formulation, can be added appropriately. Good. In addition, in order to further enhance the effect of protecting against UV damage, it is of course effective to add a UV blocker or UV absorber.
【0010】p−ヒドロキシベンズアルデヒドの含有量
は使用形態,使用目的,使用方法,剤形等によって異な
るが、例えば化粧料では0.001〜3%(重量%、以
下同じ)、軟膏剤では0.01〜10%である。The content of p-hydroxybenzaldehyde varies depending on the form of use, purpose of use, method of use, dosage form and the like. For example, 0.001 to 3% (by weight, the same applies hereinafter) for cosmetics and 0. It is from 01 to 10%.
【0011】[0011]
【実施例】以下に実施例を挙げて本発明を更に詳細に説
明するが、下記実施例は本発明を制限するものではな
く、前・後記の趣旨を逸脱しない範囲で変更実施するこ
とは全て本発明の技術的範囲に包含される。 実施例1 本発明の紫外線障害防御外用剤を用いた代表的な処方例
を挙げるが、勿論これらのみに限定されるものではな
い。The present invention will be described in more detail with reference to the following examples, but the following examples are not intended to limit the present invention, and all modifications can be made without departing from the spirit of the preceding and the following. It is included in the technical scope of the present invention. Example 1 Representative formulation examples using the external preparation for ultraviolet ray protection of the present invention are listed, but of course the present invention is not limited thereto.
【0012】 <ローション剤> 重量部 ・ポリオキシエチレン硬化ヒマシ油 1.0 ・エタノール 15.0 ・クエン酸 0.1 ・クエン酸ナトリウム 0.3 ・1,3−ブチレングリコール 4.0 ・p−ヒドロキシベンズアルデヒド 0.05 ・防腐剤 適量 ・香料 微量 ・精製水 残余 各成分を均一に撹拌、混合、溶解し、ローション剤を得
た。<Lotion> Part by weight • Polyoxyethylene hydrogenated castor oil 1.0 • Ethanol 15.0 • Citric acid 0.1 • Sodium citrate 0.3 • 1,3-Butylene glycol 4.0 • p- Hydroxybenzaldehyde 0.05 ・ Preservative proper amount ・ Perfume trace amount ・ Purified water Residual components were uniformly stirred, mixed and dissolved to obtain a lotion.
【0013】 <軟膏剤> 重量部 (A)・モノステアリン酸ポリオキシエチレンソルビタン 1.0 ・テトラオレイン酸ポリオキシエチレンソルビット 1.5 ・自己乳化型モノステアリン酸グリセリン 1.5 ・サラシミツロウ 2.0 ・パラフィン 2.0 ・ステアリン酸 3.0 ・ヘベニルアルコール 3.0 ・シアバター 12.0 ・流動パラフィン 5.0 ・メチルポリシロキサン 0.01 ・p−ヒドロキシベンズアルデヒド 0.5 ・防腐剤 適量 ・香料 微量 (B)・1,3−ブチレングリコール 5.0 ・クエン酸 0.3 ・dl−ラウロイル−L−グルタミン酸ナトリウム 0.5 ・精製水 残余 (A)に属する成分を加熱溶解し、(油相)、別に
(B)に属する成分を加熱溶解した(水相)。油相に水
相を添加して撹拌乳化後冷却して軟膏剤を得た。<Ointment> Parts by weight (A) • Polyoxyethylene sorbitan monostearate 1.0 • Polyoxyethylene sorbit tetraoleate 1.5 • Self-emulsifying glyceryl monostearate 1.5 • Salix beeswax 2. 0-paraffin 2.0-stearic acid 3.0-hevenyl alcohol 3.0-shea butter 12.0-liquid paraffin 5.0-methyl polysiloxane 0.01-p-hydroxybenzaldehyde 0.5-preservative proper amount・ Small amount of fragrance (B) ・ 1,3-butylene glycol 5.0 ・ Citric acid 0.3 ・ dl-lauroyl-L-sodium glutamate 0.5 ・ Purified water The components belonging to the residual (A) are dissolved by heating, Separately, the components belonging to (B) were dissolved by heating (oil phase) (aqueous phase). The aqueous phase was added to the oil phase, and the mixture was stirred and emulsified and then cooled to obtain an ointment.
【0014】<試験例1> 中波長紫外線(UVB)障害防御活性評価方法 Namikiらの方法(ジャーナル・オブ・アグリカル
チュラル・フード・ケミストリー(J.Agric.F
ood Chem.)、35巻、808頁、1987
年)により調整した兎赤血球膜溶液(蛋白質濃度として
2mg/ml)500μlを用意し、これに適当量の被
検物質を添加する。そして中波長紫外線(UVB)を2
0J/cm2 (2.5mW/cm2 ,133分間)照射
した後、2Mトリクロロ酢酸/1.7M塩酸溶液および
0.67%チオバルビツール酸/4mM水酸化ナトリウ
ム溶液を添加し、100℃、15分間反応させる。そし
てその反応液を室温まで冷却後3000rpm,15分
間遠心分離し、遠心上清の535nmの吸光度を測定す
る。この吸光度の中波長紫外線(UVB)未照射のコン
トロールとの差から次式によって脂質過酸化抑制率
(%)を算出する。なお、UVBの照射には東芝製FL
20S−E紫外線ランプ(最大放射波長313nm)を
用いた。 過酸化抑制率(%)=[1−{(被検物質のA535 )−
C2}/{C1−C2}]×100 但し、C1:中波長紫外線(UVB)照射コントロール
のA535 C2:中波長紫外線(UVB)未照射コントロールのA
535 を表わす。<Test Example 1> Method for evaluating mid-wavelength ultraviolet (UVB) damage protection activity Method by Namiki et al. (Journal of Agricultural Food Chemistry (J. Agric. F)
good Chem. ), 35, 808, 1987
500 μl of rabbit red blood cell membrane solution (2 mg / ml as the protein concentration) prepared according to the above (1 year), and an appropriate amount of the test substance is added thereto. And 2 medium wavelength ultraviolet (UVB)
After irradiation with 0 J / cm 2 (2.5 mW / cm 2 , 133 minutes), 2M trichloroacetic acid / 1.7M hydrochloric acid solution and 0.67% thiobarbituric acid / 4 mM sodium hydroxide solution were added, and 100 ° C. Incubate for 15 minutes. Then, the reaction solution is cooled to room temperature and then centrifuged at 3000 rpm for 15 minutes, and the absorbance of the supernatant at 535 nm is measured. The lipid peroxidation inhibition rate (%) is calculated by the following formula from the difference between this absorbance and the control which is not irradiated with medium wavelength ultraviolet (UVB). In addition, FL for Toshiba is used for UVB irradiation.
A 20S-E ultraviolet lamp (maximum emission wavelength 313 nm) was used. Peroxide inhibition rate (%) = [1-{(A 535 of test substance)-
C2} / {C1-C2}] × 100, where C1: medium wavelength ultraviolet (UVB) irradiation control A 535 C2: medium wavelength ultraviolet (UVB) non-irradiation control A
Represents 535 .
【0015】この脂質過酸化抑制率(%)を被検物質の
濃度に対してプロットし、50%の脂質過酸化抑制度を
与える濃度をIC50(Inhibited conce
ntration of 50%,μg/ml)とし
て、この値で活性の強弱を比較した。The inhibition rate (%) of lipid peroxidation was plotted against the concentration of the test substance, and the concentration giving a lipid peroxidation inhibition degree of 50% was determined by IC 50 (Inhibited conceal).
(Translation of 50%, μg / ml), and the strength of the activity was compared at this value.
【0016】供試剤として p−ヒドロキシベンズアル
デヒドを用い、比較剤としてBHA及びα−トコフェロ
ールを用いて上記の評価方法に従って中波長紫外線障害
防御活性の評価を行った。試験はp−ヒドロキシベンズ
アルデヒド添加濃度を最終濃度で25,12.5,6.
3,3.1,1.6,0.8μg/mlの6段階に変化
させて中波長紫外線障害防御活性を測定した結果、IC
50は8.6μg/mlとなった。結果を図1及び表1に
示す。Using p-hydroxybenzaldehyde as the test agent and BHA and α-tocopherol as the comparative agents, the protective activity against mid-wavelength ultraviolet rays was evaluated according to the above evaluation method. The test was carried out by adding p-hydroxybenzaldehyde at a final concentration of 25, 12.5, 6.
As a result of measuring the mid-wavelength ultraviolet ray protective activity by changing it in 6 steps of 3, 3.1, 1.6 and 0.8 μg / ml, IC
50 was 8.6 μg / ml. The results are shown in Figure 1 and Table 1.
【0017】[0017]
【表1】 [Table 1]
【0018】表1からも明らかなようにp−ヒドロキシ
ベンズアルデヒドの中波長紫外線障害防御活性はBHA
(IC50:2.0μg/ml)よりは低いもののα−ト
コフェロール(IC50:60μg/ml)と比較すると
約7倍の活性を有していることが分かる。As is apparent from Table 1, the protective activity against p-hydroxybenzaldehyde in the medium wavelength ultraviolet ray is BHA.
Although it is lower than (IC 50 : 2.0 μg / ml), it has about 7 times the activity as compared with α-tocopherol (IC 50 : 60 μg / ml).
【0019】[0019]
【発明の効果】本発明は以上のように構成されており、
従来の紫外線吸収剤(サンスクリーン剤)とは全く異な
った新しい観点に立ち、紫外線暴露によって起こる皮膚
障害そのものを緩和・抑制することのできる紫外線障害
防御剤を提供できるようになった。The present invention is configured as described above,
From a new viewpoint completely different from the conventional ultraviolet absorber (sunscreen agent), it has become possible to provide an ultraviolet damage protector capable of alleviating and suppressing the skin damage itself caused by UV exposure.
【図1】被検物濃度と中波長紫外線障害防御活性との関
係を示すグラフである。FIG. 1 is a graph showing the relationship between the concentration of a test substance and the protective activity against medium wavelength ultraviolet rays.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/11 ADA 9454−4C (72)発明者 高原 義昌 茨城県つくば市観音台1丁目25番14号 株 式会社神戸製鋼所筑波研究地区内─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 6 Identification number Internal reference number FI Technical indication location A61K 31/11 ADA 9454-4C (72) Inventor Yoshimasa Takahara 1-25 Kannondai, Tsukuba-shi, Ibaraki No. 14 Stock Company Kobe Steel Works Tsukuba Research Area
Claims (1)
ルデヒドを有効成分として含有することを特徴とする紫
外線障害防御外用剤。 【化1】 1. An external preparation for protecting against UV damage, which comprises p-hydroxybenzaldehyde represented by the following formula as an active ingredient. [Chemical 1]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29159892A JPH072640A (en) | 1992-10-29 | 1992-10-29 | External preparation for protecting ultraviolet disorder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29159892A JPH072640A (en) | 1992-10-29 | 1992-10-29 | External preparation for protecting ultraviolet disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH072640A true JPH072640A (en) | 1995-01-06 |
Family
ID=17771018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29159892A Withdrawn JPH072640A (en) | 1992-10-29 | 1992-10-29 | External preparation for protecting ultraviolet disorder |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH072640A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180303B1 (en) | 1998-06-12 | 2001-01-30 | Canon Kabushiki Kaisha | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus, and process for producing the same photosensitive member |
WO2003043621A1 (en) * | 2001-11-16 | 2003-05-30 | Cutanix Corporation | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
WO2005030233A1 (en) * | 2003-09-26 | 2005-04-07 | Nichirei Foods Inc. | Active oxygen scavenging agent and process for producing the same |
US20100284942A1 (en) * | 2006-12-15 | 2010-11-11 | Givaudan Sa | Compositions |
US8236288B2 (en) | 2011-01-07 | 2012-08-07 | Skinmedica, Inc. | Melanin modification compositions and methods of use |
US8246969B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
-
1992
- 1992-10-29 JP JP29159892A patent/JPH072640A/en not_active Withdrawn
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180303B1 (en) | 1998-06-12 | 2001-01-30 | Canon Kabushiki Kaisha | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus, and process for producing the same photosensitive member |
US9107874B2 (en) | 2001-11-16 | 2015-08-18 | Allergan, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
EA009281B1 (en) * | 2001-11-16 | 2007-12-28 | Катаникс Корпорейшн | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
US8268336B2 (en) | 2001-11-16 | 2012-09-18 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
US8246969B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
US8496951B2 (en) | 2001-11-16 | 2013-07-30 | Allergan, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
US8246971B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatment |
US10702515B2 (en) | 2001-11-16 | 2020-07-07 | Allergan, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
US9895361B2 (en) | 2001-11-16 | 2018-02-20 | Allergan, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
WO2003043621A1 (en) * | 2001-11-16 | 2003-05-30 | Cutanix Corporation | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
WO2005030233A1 (en) * | 2003-09-26 | 2005-04-07 | Nichirei Foods Inc. | Active oxygen scavenging agent and process for producing the same |
US9192559B2 (en) * | 2006-12-15 | 2015-11-24 | Givaudan Sa | Compositions |
US20100284942A1 (en) * | 2006-12-15 | 2010-11-11 | Givaudan Sa | Compositions |
US8236288B2 (en) | 2011-01-07 | 2012-08-07 | Skinmedica, Inc. | Melanin modification compositions and methods of use |
US9044404B2 (en) | 2011-01-07 | 2015-06-02 | Allergan, Inc. | Melanin modification compositions and methods of use |
US8778315B2 (en) | 2011-01-07 | 2014-07-15 | Allergan, Inc. | Melanin modification compositions and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3522378B2 (en) | Composition containing a photocatalytic metal oxide and tocopherol and its use in the cosmetics field, etc. | |
EP0633017B1 (en) | Cosmetic and dermatologic compositions containing delta-aminolevulinic acid | |
EP1891929B1 (en) | Skin cosmetic and wrinkle-reducing agent | |
EP0656774B1 (en) | Cosmetic and dermatological sunscreen compositions containing thiols and/or thiol derivates | |
JPS636526B2 (en) | ||
EP0686026B1 (en) | Synergistic combinations of sunscreening substances, cosmetic and dermatological compositions containing such combinations | |
EP0686027B1 (en) | Verwendung eines phenolischen Diterpens zur Herstellung einer Zusammensetzung zur therapeutischen Verwendung auf der Haut | |
KR101917774B1 (en) | A preservative composition of cosmetics comprising Nigella sativa seed extract as an active ingredient | |
JPH0892057A (en) | Cosmetic blended with extract of seed of coffee tree | |
JP2003533462A (en) | Use of ergothioneine and / or a derivative thereof as an antifouling agent | |
US20090069416A1 (en) | Cosmetic Composition for Skin and Wrinkle Improver | |
JPH11505818A (en) | Cosmetic or dermatological preparations containing phytic acid | |
JPH072640A (en) | External preparation for protecting ultraviolet disorder | |
JPH07101844A (en) | Multilayered emulsion | |
JPH1025220A (en) | Preparation for external use for skin | |
JP4934280B2 (en) | Wrinkle improving agent | |
JPH10167957A (en) | Intercellular adhesion suppressing agent | |
JP6157659B1 (en) | Synergistic compositions, formulations and related methods for reducing UV-induced lipid peroxidation | |
JP2004331602A (en) | Skin care preparation for external use | |
JPH0725660B2 (en) | Cosmetics with anti-inflammatory properties against sunburn | |
JPH07149620A (en) | Sunburn preventive agent | |
JP3207996B2 (en) | Sunscreen cosmetics | |
JPH0748239A (en) | External preparation for blocking ultraviolet disorder | |
JPH0692833A (en) | Skin external agent | |
JP2506388B2 (en) | Topical skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20000104 |